期刊
ANNALS OF ONCOLOGY
卷 24, 期 3, 页码 702-709出版社
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mds533
关键词
adenocarcinoma; bevacizumab; chemotherapy; gastric; oesophagus; peri-operative
类别
资金
- Cancer Research UK [CRUK/06/025, C1504/A6410]
- MRC
- Roche
- NIHR Biomedical Research Centre
- Medical Research Council [MC_U122861327] Funding Source: researchfish
- MRC [MC_U122861327] Funding Source: UKRI
Background: Pen-operative chemotherapy and surgery is a standard treatment of localised oesophagogastric adenocarcinoma; however, the outcomes remain poor. Patients and methods: ST03 is a multicentre, randomised, phase II/III study comparing pen-operative ECX with or without bevacizumab (ECX-B). The primary outcome measure of phase II (n = 200) was safety, specifically gastrointestinal (GI) perforation rates and cardiotoxicity. Results: Two hundred patients were randomised between October 2007 and April 2010. Ninety-one/101 (90%) ECX and 86/99 (87%) ECX-B patients completed pre-operative chemotherapy; 7 ECX and 9 ECX-B patients stopped due to toxicity. Gastrointestinal perforations (3 ECX, 1 ECX-B), cardiac events (1 ECX, 4 ECX-B) and venous thromboembolic events (VEs, 8 ECX, 7 ECX-B) were uncommon. Arterial thromboembolic events (ATEs, myocardial infarction (MI) or cerebrovascular accident) were more frequent with ECX-B (5 versus 1 with ECx). Delayed wound healing, anastomotic leaks and GI bleeding rates were similar.More asymptomatic left ventricular ejection fraction (LVEF) falls (>= 15% and/or to <50%) occurred with ECX-B (21.2% versus 11.1% with ECX). Clinically significant falls (>= 10% to below lower limit of normal, LLN) occurred in (15.3%) and (8.9%) respectively, with no associated cardiac failure (median 22 months follow-up). Conclusions: Addition of bevacizumab to pen-operative ECX chemotherapy is feasible with acceptable toxicity and no negative impact on surgical outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据